While not exclusively focused on angiogenesis, a clinical trial includes the investigation of PTPRJ genetic variations in cancer patients, which may provide insights into its role in tumor angiogenesis and potential therapeutic targeting. This evidence concerns the gene PTPRJ and neoplasm.